This study evaluates the safety, tolerability and preliminary antitumor activity of Glecirasib (JAB-21822), a KRAS G12C inhibitor, in locally advanced or metastatic NSCLC with concurrent KRAS G12C and LKB1 mutation and KEAP wild type either treatment naive or at least one-line prior therapy for advance disease. The gene discussed is STK11; the disease is non-small cell lung carcinoma.